

The clinical uses of vinpocetine: An educational article and expert opinion

Aamir Jalal Al Mosawi

Advisor Doctor and expert trainer, The National Training and Development Center and Baghdad Medical City, Iraq.

***Correspondence Author:** Aamir Jalal Al Mosawi, Advisor Doctor and expert trainer, The National Training and Development Center and Baghdad Medical City, Iraq.

Received Date: May 07, 2024 | **Accepted Date:** May 14, 2024 | **Published Date:** May 21, 2024

Citation: Aamir Jalal Al Mosawi, (2024), The clinical uses of vinpocetine: An educational article and expert opinion, *Journal of Scientific Research and Biomedical Informatics*, 3(3); **DOI:** 10.31579/2834-8745/016

Copyright: © 2024, Aamir Jalal Al Mosawi. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract:

Vinpocetine (Ethyl-apovincamate) is a derivative of vincamine which is an alkaloid compound. It has been used for years in the treatment of chronic cerebral disorders in few countries. and its beneficial effects have been attributed mostly to an improved blood flow and metabolism of the affected brain tissues. The aim of this paper is to provide an overview of the possible clinical uses of vinpocetine that are supported by scientific evidence.

Expert opinion: The current evidence-based expert opinion suggests that vinpocetine as a monotherapy is unlikely to be beneficial in any disorder. However, there is some evidence suggesting that the use of vinpocetine as adjunctive therapy in patients with chronic cerebrovascular ischemia can have a beneficial effect on cognitive functions and the quality of life.

Keywords: Vinpocetine; clinical uses; expert opinion

Introduction

Vinpocetine (Ethyl-apovincamate) is a derivative of vincamine which is an alkaloid compound. Vinpocetine intravenous infusion was reported to increase cerebral blood flow measured by the two-minute radioactive Xenon technique in healthy volunteers [3].

During the 1970s and early 1980s the use of vinpocetine in the treatment hearing defects, Ménière disease, motion sickness, vascular retinal lesions, circulatory insufficiency of the lower limbs, and cerebrovascular disorders was suggested [1-8]. In 1985, Subhan and Hindmarch reported a placebo-controlled study which included 12 healthy female volunteers. The study showed that vinpocetine 40 mg three times daily can considerably improve memory [9]. In 1986, Domżał and colleagues reported a study which included patients with acute ischemic stroke. 14 patients were treated with intravenous vinpocetine, and 12 patients received aminophylline twice daily for 10 days. Of the 14 patients treated with vinpocetine, two patients died and 12 experienced improvement. In the 10 patients treated with aminophylline, 5 patients died, and two patients didn't improve. There was no correlation between clinical improvement and CT-scan improvement. However, vinpocetine treatment was associated a considerable improvement on CT-scan changes [10]. In 1987, Balestreri and colleagues reported a placebo-controlled study which included elderly patients with chronic cerebral dysfunction. 42 patients were treated with vinpocetine 30 mg in 3 divided doses daily for one month, followed by 15 mg in 3 divided doses daily for 2 months. 42 patients received placebo for the 3 months. Vinpocetine treatment was associated with considerable improvement in mental function and without

the occurrence of serious side effects [11]. In 1990, Kiss from Hungary reported a study which included 40 postmenopausal female patients which showed that vinpocetine can have adjuvant role in the treatment of climacteric symptoms [12]. In 1991, Dutov et al reported a study which suggested that when vinpocetine is given to children who had experienced birth trauma, it can beneficial effects with reduction of the possible convulsive tendency, and may contribute to a better psychomotor development [13]. Also in 1991, Hindmarch and colleagues from England reported a placebo-controlled study which included 203 patients who had mild to moderate organic psycho-syndromes such as primary dementia. Patients received either vinpocetine 30 mg daily in 3 divided doses, vinpocetine 60 mg daily in 3 divided doses for 16 weeks, or received placebo. Vinpocetine was not associated with relevant side-effects when compared with placebo. Both doses of vinpocetine were associated with considerable improvements in cognitive performance, depressive symptoms, and quality of life [14]. In 1992, Burtsev et al reported their 10-year experience with the use of vinpocetine in the treatment of 967 patients with a variety of cerebrovascular disorder. They found that vinpocetine is more likely to have beneficial effects when used in patients with early forms and primary forms of chronic neuro-circulatory disorders associated with evidence of brain blood supply insufficiency, and in circulatory encephalopathy. Vinpocetine was associated with symptomatic improvement when used in the treatment of ischemic stroke. Burtsev et al suggested that vinpocetine should not be used in severe cerebral hypertensive crises, acute cardio-cerebral or cerebro-cardiac

syndrome, and, disorders associated with marked abnormality of heart rhythm [15].

In 2001, Feigin et al from Germany reported a study which included 30 patients with acute ischemic stroke diagnosed by brain CT-scan. Within 72 hours of the onset of stroke, 15 patients received low-molecular weight dextran plus vinpocetine, and 15 patients received low-molecular weight dextran only. Vinpocetine treatment was associated with a better outcome. Vinpocetine was not associated with important adverse effects [16]. In 2002, Bönöczk and colleagues from Hungary reported a placebo-controlled study which included forty-three patients who had ischemic stroke who received either a single-dose intravenous infusion of vinpocetine (20 mg in 500 ml saline) or placebo (500 ml saline).

Vinpocetine was associated with an increase in cerebral perfusion and parenchymal oxygen extraction as measured by trans-cranial Doppler and near infrared spectroscopy [17]. In 2007, Valikovics reported a study which included patients who had ischemic cerebrovascular stroke associated with mild cognitive defect who were treated with oral vinpocetine for two weeks. Treatment was associated with a marked improvement in cognitive functions that was attributed to an increase in blood flow velocity which was measured by trans-cranial Doppler [18]. In 2009, Chukanova reported a controlled study which included patients with chronic cerebrovascular insufficiency. 138 patients were treated with oral vinpocetine 30 mg daily plus the conventional hypotensive and antithrombotic medications for three months. 98 control patients received the conventional medications only. The addition of vinpocetine resulted in more improvement in the neurological symptoms than the improvement in the control patients. Patients who received vinpocetine also experienced marked reduction in the risk of progression of the cerebrovascular insufficiency, and in the development of transient ischemic attacks, and ischemic strokes, when compared to the control patients [19]. Also in 2009, Afon'kin et al reported a study which included fifty patients with chronic neurosensory hearing impairment treated with vinpocetine. Treatment was associated with marked improvement of audiologic parameters in 80% of the patients with reduction of tympanophonia [20]. In 2016, Zhang et al from China reported a study which included 610 patients with acute cerebral infarction. 469 patients were treated with citicoline (cytidine diphosphate choline) 400-500 mg plus aspirin 75-100 mg or clopidogrel 75 mg one time daily plus vinpocetine 30 mg intravenously one time daily for one week. 141 patients were treated with citicoline 400-500 mg plus aspirin 75-100 mg or clopidogrel 75 mg one time daily for one week. The patients' hypertension, hyperglycemia, hyperlipidemia, and intracranial hypertension were treated as appropriate. Three months after treatment, patients who received vinpocetine experienced marked improvement in cognitive and neurological functions, and quality of life. The beneficial effects of vinpocetine were attributed increasing cerebral blood flow [21]. In 2019, Garza-Morales et al from Mexico reported a placebo-controlled study which included 87 patients who had focal epilepsy treated with one to three antiepileptic medications. Forty-one patients received vinpocetine (2 mg per kg daily) as an adjuvant therapy and forty-six patients received placebo. 69% of the patients who received vinpocetine experienced a 50% reduction in seizures, while only 13% of the patients who received placebo experienced reduction in seizures. There were no important differences in the occurrence of adverse effects in patients who received vinpocetine and the patients who received placebo. The most frequent adverse effect seen with vinpocetine was headache which occurred in 7.9% and diplopia which occurred in 5.2%. Therefore, vinpocetine was found to be well tolerated and more effective than placebo in decreasing seizure frequency ($p < 0.0001$) [22]. Gutiérrez-Farfán et al from Mexico reported a one-year study which included adults who had acquired sensorineural hearing impairment who were treated with vinpocetine (30 mg daily in 3 divided doses. Treatment had a

beneficial effect by stopping the deterioration and leading to some improvement [23]. In 2022, Panda et al from India reported the findings of a systematic review and meta-Analysis which included 4 placebo-controlled studies involving 601 treated with vinpocetine, and 236 patients received placebo. The patients who received vinpocetine experienced less deaths and less severe disability than the patients who received placebo, at both one month and three months. The findings of Panda et al et al suggested that vinpocetine has the potential to be beneficial in the treatment of ischemic cerebral stroke, and may help in reducing the associated disability [24].

Expert opinion

The current evidence-based expert opinion suggests that vinpocetine as a monotherapy is unlikely to be beneficial in any disorder. However, there is some evidence suggesting that the use of vinpocetine as adjunctive therapy in patients with chronic cerebrovascular ischemia can have a beneficial effect on cognitive functions and the quality of life.

Conflict of interest: None.

References

1. Ordögh B, Sárossy D, Klimstein G (1978). Therapeutic action of Cavinton in hearing defects of neurological origin. *Ther Hung* ; 26(1):16-19.
2. Jasper A (1978). Action of Cavinton on hearing defects of different origin. *Ther Hung*; 26(4):181-184.
3. Lim CC, Cook PJ, James IM (1980). The effect of an acute infusion of vincamine and ethyl apovincamate on cerebral blood flow in healthy volunteers. *Br J Clin Pharmacol* Jan; 9(1):100-101.
4. Nikolaev MP, Konstantinova ZD, Mertsalova ON, Sheremet AS (1980). Perspektiva primeneniia kavintona dlia lecheniia bol'nykh s bolezni'u Men'era Prospects of using cavinton for treating Ménière's disease. *Vestn Otorinolaringol* May-Jun ;(3):18-22.
5. Oláh Z, Potocký M (1981). Použitie prípravku "Cavinton" v liečbe cievnych zmien sietnice [Treatment of vascular retinal lesions with Cavinton]. *Cesk Oftalmol* Jan; 37(1):19-23.
6. Jonderko G, Szramek-Urbaniak A, Bednarczyk-Kałużna M (1982). Użyteczność Cavintonu i Halidoru jako leków rozszerzających naczynia w niedostatecznym ukrwieniu kończyn dolnych [Usefulness of vasodilator agents Cavinton and Halidor in circulatory insufficiency of the lower limbs]. *Przegl Lek* ; 39(9):617-620.
7. Bodo D, Kotovskaia AR, Galle RR, Gavrilova LN, Gusakova GA (1982). Effektivnost' preparata kavinton v profilaktike bolezni dvizheniia [Effectiveness of the preparation Gavinton in preventing motion sickness]. *Kosm Biol Aviakosm Med* May-Jun; 16(3):49-51.
8. Kalvach P, Bauer J, Ságová V (1982). Cavinton v terapii cerebrovaskulárních poruch Cavinton in the therapy of cerebrovascular disorders]. *Cesk Neurol Neurochir* Nov; 45 (6): 380-385.
9. Subhan Z, Hindmarch I (1985). Psychopharmacological effects of vinpocetine in normal healthy volunteers. *Eur J Clin Pharmacol* ; 28(5):567-571.
10. Domżał T, Kozłowski P, Zaleska B (1986). Cavinton w leczeniu niedokrwiennych udarów mózgu. Ocena kliniczna i komputerowo-tomograficzna (CT) Cavinton in the treatment of ischemic cerebral stroke. Clinical and computerized-tomographic evaluation. *Neurol Neurochir Pol* May-Jun; 20(3):234-40 .
11. Balestreri R, Fontana L, Astengo F (1987). A double-blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction. *J Am Geriatr Soc* May; 35(5):425-30.

12. Kiss E (1990). Adjuvant effect of cavinton in the treatment of climacteric symptoms. *Ther Hung.* 38(4):170-173.
13. Dutov AA, Gal'tvanitsa GA, Volkova VA, Sukhanova ON, Lavrishcheva TG, Petrov AP (1991). Kavinton v profilaktike sudorozhnogo sindroma u detei, perenesshikh rodovuiu travmu Cavinton in the prevention of the convulsive syndrome in children after birth injury. *Zh Nevropatol Psikhiatr Im S S Korsakova* ; 91(8):21-22.
14. Hindmarch I, Fuchs HH, Erzigkeit H (1991). Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes. *Int Clin Psychopharmacol Spring*; 6(1):31-43.
15. Burtsev EM, Savkov VS, Shprakh VV, Burtsev ME (1992). 10-letnii opyt primeneniia kavintona pri tserebrovaskuliarnykh narusheniiaxh 10-year experience with using Cavinton in cerebrovascular disorders. *Zh Nevropatol Psikhiatr Im S S Korsakova.* ; 92(1):56-60.
16. Feigin VL, Doronin BM, Popova TF, Gribatcheva EV, Tchervov DV (2001). Vinpocetine treatment in acute ischaemic stroke: a pilot single-blind randomized clinical trial. *Eur J Neurol Jan*; 8(1):81-85.
17. Bönöczk P, Panczel G, Nagy Z (2002). Vinpocetine increases cerebral blood flow and oxygenation in stroke patients: a near infrared spectroscopy and transcranial Doppler study. *Eur J Ultrasound Jun*; 15(1-2):85-91.
18. Valikovics A (2007). A vinpocetin agyi véráramlásra és kognitív funkciókra gyakorolt hatásának vizsgálata [Investigation of the effect of vinpocetine on cerebral blood flow and cognitive functions]. *Ideggyogy Sz* Jul 30; 60(7-8):301-310.
19. Chukanova EI (2009). Cavinton in the complex treatment of patients with chronic cerebrovascular insufficiency. *Zh Nevrol Psikhiatr Im S S Korsakova* ; 109(9):35-9 .
20. Afon'kin VIu, Dobretsov KG, Sipkin AV (2009). The new scheme of cavinton application to the treatment of chronic neurosensory loss of hearing. *Vestn Otorinolaringol* ; (6): 69-70.
21. Zhang W, Huang Y, Li Y, Tan L, Nao J, Hu H, et.al (2016). Efficacy and Safety of Vinpocetine as Part of Treatment for Acute Cerebral Infarction: A Randomized, Open-Label, Controlled, Multicenter CAVIN (Chinese Assessment for Vinpocetine in Neurology) Trial. *Clin Drug Investig Sep*; 36(9):697-704.
22. Garza-Morales S, Briceño-González E, Ceja-Moreno H, Ruiz-Sandoval JL, Góngora-Rivera F, (2019). Extended-release vinpocetine: a possible adjuvant treatment for focal onset epileptic seizures. *Bol Med Hosp Infant Mex*; 76(5):215-224.
23. Gutiérrez-Farfán I, Reyes-Legorreta C, Solís-Olguín M, Alatorre-Miguel E,et.al (2021). Evaluation of vinpocetine as a therapy in patients with sensorineural hearing loss: A phase II, open-label, single-center study. *J Pharmacol Sci. Apr*; 145(4):313-318.
24. Panda PK, Ramachandran A, Panda P, Sharawat IK (2022). Safety and Efficacy of Vinpocetine as a Neuroprotective Agent in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis. *Neurocrit Care* 2022 Aug; 37(1):314-325.

Ready to submit your research? Choose ClinicSearch and benefit from:

- fast, convenient online submission
- rigorous peer review by experienced research in your field
- rapid publication on acceptance
- authors retain copyrights
- unique DOI for all articles
- immediate, unrestricted online access

At ClinicSearch, research is always in progress.

Learn more <https://www.clinicsearchonline.org/journals/journal-of-scientific-research-and-biomedical-informatics>



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.